Additional file 1 of Comparison of tracer kinetic models for 68Ga-PSMA-11 PET in intermediate-risk primary prostate cancer patients

Additional file 1. Additional supporting figures. Referenced materials include additional parameter regressions (S1), patient-matched parameter values for lesion and reference prostate (S2), comparison of kinetic parameter values by prostatic zone (S3), and reference prostate chi-square goodness-of-fit values by prostatic zone for the 2T3k kinetic model (S4)

Pressure-Stabilized Cubic Perovskite Oxyhydride BaScO₂H

We report a scandium oxyhydride BaScO₂H prepared by solid state reaction under high pressure. Rietveld refinements against powder synchrotron X-ray and neutron diffraction data revealed that BaScO₂H adopts the ideal cubic perovskite structure (<i>Pm</i>3̅<i>m</i>), where oxide (O^2–) and hydride (H^–) anions are disordered. ¹H nuclear magnetic resonance (NMR) spectroscopy provides a positive chemical shift of about +4.4 ppm, which can be understood by the distance to the nearest (and possibly the next nearest) cation from the H nucleus. A further analysis of the NMR data and calculations based on <i>ab initio</i> random structure searches suggest a partial <i>cis</i> preference in ScO₄H₂ octahedra. The present oxyhydride, if compositionally or structurally tuned, may become a candidate for H^– conductors

Bisphosphonate-Anchored PEGylation and Radiolabeling of Superparamagnetic Iron Oxide: Long-Circulating Nanoparticles for <i>in Vivo</i> Multimodal (T1 MRI-SPECT) Imaging

The efficient delivery of nanomaterials to specific targets for <i>in vivo</i> biomedical imaging is hindered by rapid sequestration by the reticuloendothelial system (RES) and consequent short circulation times. To overcome these two problems, we have prepared a new stealth PEG polymer conjugate containing a terminal 1,1-bisphosphonate (BP) group for strong and stable binding to the surface of ultrasmall-superparamagnetic oxide nanomaterials (USPIOs). This polymer, PEG(5)-BP, can be used to exchange the hydrophobic surfactants commonly used in the synthesis of USPIOs very efficiently and at room temperature using a simple method in 1 h. The resulting nanoparticles, PEG(5)-BP-USPIOs are stable in water or saline for at least 7 months and display a near-zero ζ-potential at neutral pH. The longitudinal (<i>r</i>₁) and transverse (<i>r</i>₂) relaxivities were measured at a clinically relevant magnetic field (3 T), revealing a high <i>r</i>₁ of 9.5 mM^–1 s^–1 and low <i>r</i>₂/<i>r</i>₁ ratio of 2.97, making these USPIOs attractive as T1-weighted MRI contrast agents at high magnetic fields. The strong T1-effect was demonstrated <i>in vivo</i>, revealing that PEG(5)-BP-USPIOs remain in the bloodstream and enhance its signal 6-fold, allowing the visualization of blood vessels and vascular organs with high spatial definition. Furthermore, the optimal relaxivity properties allow us to inject a dose 4 times lower than with other USPIOs. PEG(5)-BP-USPIOs can also be labeled using a radiolabeled-BP for visualization with single photon emission computed tomography (SPECT), and thus affording dual-modality contrast. The SPECT studies confirmed low RES uptake and long blood circulation times (<i>t</i>_1/2 = 2.97 h). These results demonstrate the potential of PEG(5)-BP-USPIOs for the development of targeted multimodal imaging agents for molecular imaging